{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T17:09:07Z","timestamp":1788714547050,"version":"build-2803163510"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T00:00:00Z","timestamp":1788652800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013669","name":"Ionis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013669","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"DOI":"10.1007\/s40273-026-01655-8","type":"journal-article","created":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:20:26Z","timestamp":1788711626000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value of Knowing the Risk of Developing a Neurodegenerative Disease: A Discrete Choice Experiment"],"prefix":"10.1007","author":[{"given":"Patricia G.","family":"Synnott","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Ollendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Kymes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna L.","family":"Bernstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Vera-Llonch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,6]]},"reference":[{"key":"1655_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031851","author":"RNL Lamptey","year":"2022","unstructured":"Lamptey RNL, Chaulagain B, Trivedi R, Gothwal A, Layek B, Singh J. A review of the common neurodegenerative disorders: current therapeutic approaches and the potential role of nanotherapeutics. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms23031851.","journal-title":"Int J Mol Sci"},{"key":"1655_CR2","unstructured":"Neurodegenerative diseases18 June 2024. Available from: https:\/\/my.clevelandclinic.org\/health\/diseases\/24976-neurodegenerative-diseases."},{"key":"1655_CR3","unstructured":"Thorpe KE, Levey AI, Thomas J. U.S. Burden of neurodegenerative disease literature review summary2021 9 July 2024. Available from: https:\/\/www.fightchronicdisease.org\/_files\/ugd\/b11210_a27be18c12144b10afaf7b0bef3302fa.pdf."},{"key":"1655_CR4","unstructured":"Prevalence & incidence18 June 2024. Available from: https:\/\/www.parkinson.org\/understanding-parkinsons\/statistics\/prevalence-incidence."},{"issue":"5","key":"1655_CR5","doi-asserted-by":"publisher","first-page":"3708","DOI":"10.1002\/alz.13809","volume":"20","author":"Alzheimer's disease facts and figures","year":"2024","unstructured":"Alzheimer\u2019s disease facts and figures. Alzheimers Dement. 2024;20(5):3708\u2013821.","journal-title":"Alzheimers Dement"},{"key":"1655_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13040638","author":"AL Halbisen","year":"2012","unstructured":"Halbisen AL, Lu CY. Trends in availability of genetic tests in the United States, 2012-2022. J Pers Med. 2012. https:\/\/doi.org\/10.3390\/jpm13040638.","journal-title":"J Pers Med"},{"key":"1655_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2020.104871","volume":"141","author":"JS Roberts","year":"2020","unstructured":"Roberts JS, Patterson AK, Uhlmann WR. Genetic testing for neurodegenerative diseases: ethical and health communication challenges. Neurobiol Dis. 2020;141:104871.","journal-title":"Neurobiol Dis"},{"issue":"6","key":"1655_CR8","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1097\/GIM.0b013e31821d69b8","volume":"13","author":"JS Goldman","year":"2011","unstructured":"Goldman JS, Hahn SE, Catania JW, LaRusse-Eckert S, Butson MB, Rumbaugh M, et al. Genetic counseling and testing for Alzheimer disease: joint practice guidelines of the American College of Medical Genetics and the National Society of Genetic Counselors. Genet Med. 2011;13(6):597\u2013605.","journal-title":"Genet Med"},{"issue":"2","key":"1655_CR9","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1001\/archneur.61.2.213","volume":"61","author":"JS Goldman","year":"2004","unstructured":"Goldman JS, Miller BL, Safar J, de Tourreil S, Martindale JL, Prusiner SB, et al. When sporadic disease is not sporadic: the potential for genetic etiology. Arch Neurol. 2004;61(2):213\u20136.","journal-title":"Arch Neurol"},{"issue":"5","key":"1655_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/gim.2015.117","volume":"18","author":"C Van Cauwenberghe","year":"2016","unstructured":"Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421\u201330.","journal-title":"Genet Med"},{"issue":"3","key":"1655_CR11","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41431-020-00744-2","volume":"29","author":"SE Walcott","year":"2021","unstructured":"Walcott SE, Miller FA, Dunsmore K, Lazor T, Feldman BM, Hayeems RZ. Measuring clinical utility in the context of genetic testing: a scoping review. Eur J Hum Genet. 2021;29(3):378\u201386.","journal-title":"Eur J Hum Genet"},{"key":"1655_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.eplepsyres.2017.02.001","volume":"131","author":"P Perucca","year":"2017","unstructured":"Perucca P, Scheffer IE, Harvey AS, James PA, Lunke S, Thorne N, et al. Real-world utility of whole exome sequencing with targeted gene analysis for focal epilepsy. Epilepsy Res. 2017;131:1\u20138.","journal-title":"Epilepsy Res"},{"key":"1655_CR13","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jpsychires.2017.01.015","volume":"89","author":"M Sharma","year":"2017","unstructured":"Sharma M, Kantorovich S, Lee C, Anand N, Blanchard J, Fung ET, et al. An observational study of the impact of genetic testing for pain perception in the clinical management of chronic non-cancer pain. J Psychiatr Res. 2017;89:65\u201372.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"1655_CR14","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.cancergen.2015.12.013","volume":"209","author":"C Ricker","year":"2016","unstructured":"Ricker C, Culver JO, Lowstuter K, Sturgeon D, Sturgeon JD, Chanock CR, et al. Increased yield of actionable mutations using multi-gene panels to assess hereditary cancer susceptibility in an ethnically diverse clinical cohort. Cancer Genet. 2016;209(4):130\u20137.","journal-title":"Cancer Genet"},{"issue":"2","key":"1655_CR15","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jval.2017.12.007","volume":"21","author":"DN Lakdawalla","year":"2018","unstructured":"Lakdawalla DN, Doshi JA, Garrison LP Jr., Phelps CE, Basu A, Danzon PM. Defining elements of value in health care-a health economics approach: an ISPOR special task force report [3]. Value Health. 2018;21(2):131\u20139.","journal-title":"Value Health"},{"issue":"10","key":"1655_CR16","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.gim.2022.06.003","volume":"24","author":"JS Goldman","year":"2022","unstructured":"Goldman JS, Vallabh SM. Genetic counseling for prion disease: updates and best practices. Genet Med. 2022;24(10):1993\u20132003.","journal-title":"Genet Med"},{"issue":"12","key":"1655_CR17","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ejhg.2014.42","volume":"22","author":"J Owen","year":"2014","unstructured":"Owen J, Beck J, Campbell T, Adamson G, Gorham M, Thompson A, et al. Predictive testing for inherited prion disease: report of 22 years experience. Eur J Hum Genet. 2014;22(12):1351\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1655_CR18","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a036525","author":"JS Goldman","year":"2020","unstructured":"Goldman JS. Predictive genetic counseling for neurodegenerative diseases: past, present, and future. Cold Spring Harb Perspect Med. 2020. https:\/\/doi.org\/10.1101\/cshperspect.a036525.","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"12","key":"1655_CR19","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/gtmb.2011.0028","volume":"15","author":"IM Kopits","year":"2011","unstructured":"Kopits IM, Chen C, Roberts JS, Uhlmann W, Green RC. Willingness to pay for genetic testing for Alzheimer\u2019s disease: a measure of personal utility. Genet Test Mol Biomarkers. 2011;15(12):871\u20135.","journal-title":"Genet Test Mol Biomarkers"},{"key":"1655_CR20","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.socscimed.2018.08.015","volume":"214","author":"C Peyron","year":"2018","unstructured":"Peyron C, P\u00e9lissier A, B\u00e9jean S. Preference heterogeneity with respect to whole genome sequencing. A discrete choice experiment among parents of children with rare genetic diseases. Soc Sci Med. 2018;214:125\u201332.","journal-title":"Soc Sci Med"},{"issue":"8","key":"1655_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jval.2014.09.001","volume":"17","author":"V Kilambi","year":"2014","unstructured":"Kilambi V, Johnson FR, Gonz\u00e1lez JM, Mohamed AF. Valuations of genetic test information for treatable conditions: the case of colorectal cancer screening. Value Health. 2014;17(8):838\u201345.","journal-title":"Value Health"},{"key":"1655_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/1472-6963-13-454","volume":"13","author":"M Najafzadeh","year":"2013","unstructured":"Najafzadeh M, Johnston KM, Peacock SJ, Connors JM, Marra MA, Lynd LD, et al. Genomic testing to determine drug response: measuring preferences of the public and patients using Discrete Choice Experiment (DCE). BMC Health Serv Res. 2013;13:454.","journal-title":"BMC Health Serv Res"},{"issue":"10","key":"1655_CR23","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s40273-024-01431-6","volume":"42","author":"J Ride","year":"2024","unstructured":"Ride J, Goranitis I, Meng Y, LaBond C, Lancsar E. A reporting checklist for discrete choice experiments in health: the DIRECT checklist. Pharmacoeconomics. 2024;42(10):1161\u201375.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"1655_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.jval.2015.10.011","volume":"19","author":"A M\u00fchlbacher","year":"2016","unstructured":"M\u00fchlbacher A, Johnson FR, Yang JC, Happich M, Belger M. Do you want to hear the bad news? The value of diagnostic tests for Alzheimer\u2019s disease. Value Health. 2016;19(1):66\u201374.","journal-title":"Value Health"},{"issue":"10","key":"1655_CR25","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.mayocp.2014.05.016","volume":"89","author":"RJ Caselli","year":"2014","unstructured":"Caselli RJ, Langbaum J, Marchant GE, Lindor RA, Hunt KS, Henslin BR, et al. Public perceptions of presymptomatic testing for Alzheimer disease. Mayo Clin Proc. 2014;89(10):1389\u201396.","journal-title":"Mayo Clin Proc"},{"key":"1655_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.998302","volume":"10","author":"RB Carver","year":"2022","unstructured":"Carver RB, Fredheim NAG, Mowinckel AM, Ebmeier KP, Friedman BB, Rosness TA, et al. People\u2019s interest in brain health testing: findings from an international, online cross-sectional survey. Front Public Health. 2022;10:998302.","journal-title":"Front Public Health"},{"issue":"3","key":"1655_CR27","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1002\/hec.1704","volume":"21","author":"PJ Neumann","year":"2012","unstructured":"Neumann PJ, Cohen JT, Hammitt JK, Concannon TW, Auerbach HR, Fang C, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ. 2012;21(3):238\u201351.","journal-title":"Health Econ"},{"issue":"2","key":"1655_CR28","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/j.1524-4733.2008.00417.x","volume":"12","author":"K Howard","year":"2009","unstructured":"Howard K, Salkeld G. Does attribute framing in discrete choice experiments influence willingness to pay? Results from a discrete choice experiment in screening for colorectal cancer. Value Health. 2009;12(2):354\u201363.","journal-title":"Value Health"},{"key":"1655_CR29","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.pediatrneurol.2016.09.008","volume":"66","author":"PJ Lin","year":"2017","unstructured":"Lin PJ, Yeh WS, Neumann PJ. Willingness to pay for a newborn screening test for spinal muscular atrophy. Pediatr Neurol. 2017;66:69\u201375.","journal-title":"Pediatr Neurol"},{"issue":"3","key":"1655_CR30","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ejhg.2014.111","volume":"23","author":"S Tubeuf","year":"2015","unstructured":"Tubeuf S, Willis TA, Potrata B, Grant H, Allsop MJ, Ahmed M, et al. Willingness to pay for genetic testing for inherited retinal disease. Eur J Hum Genet. 2015;23(3):285\u201391.","journal-title":"Eur J Hum Genet"},{"key":"1655_CR31","unstructured":"Using discrete choice experiments to value health and health care: Springer Dordrecht; 2007 23 October 2007."},{"issue":"7","key":"1655_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e18256","volume":"9","author":"AS Alamri","year":"2023","unstructured":"Alamri AS, Georgiou S, Stylianou S. Discrete choice experiments: an overview on constructing D-optimal and near-optimal choice sets. Heliyon. 2023;9(7):e18256.","journal-title":"Heliyon"},{"key":"1655_CR33","unstructured":"Kuhfeld W. MR-2010C\u2014Experimental design: efficiency, coding, and choice designs experimental design: efficiency, coding, and choice designs. Mark Res Methods Sas Exp Des Choice, Conjoint, Graph Tech. 2012."},{"issue":"3","key":"1655_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1287\/mksc.1090.0508","volume":"29","author":"DG Fiebig","year":"2010","unstructured":"Fiebig DG, Keane MP, Louviere J, Wasi N. The generalized multinomial logit model: accounting for scale and coefficient heterogeneity. Mark Sci. 2010;29(3):393\u2013421.","journal-title":"Mark Sci"},{"issue":"1","key":"1655_CR35","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40271-021-00531-1","volume":"15","author":"S Ozdemir","year":"2022","unstructured":"Ozdemir S, Lee JJ, Chaudhry I, Ocampo RRQ. A systematic review of discrete choice experiments and conjoint analysis on genetic testing. Patient-Patient-Cent Outcomes Res. 2022;15(1):39\u201354.","journal-title":"Patient-Patient-Cent Outcomes Res"},{"issue":"1","key":"1655_CR36","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1186\/s13023-024-03160-7","volume":"19","author":"C Mansfield","year":"2024","unstructured":"Mansfield C, Boeri M, Coulter J, Baranowski E, Sparks S, An Haack K, et al. The value of knowing: preferences for genetic testing to diagnose rare muscle diseases. Orphanet J Rare Dis. 2024;19(1):173.","journal-title":"Orphanet J Rare Dis"},{"key":"1655_CR37","first-page":"13","volume-title":"The choice modelling approach to environmental valuation","author":"JJ Louviere","year":"2001","unstructured":"Louviere JJ. Choice experiments: an overview of concepts and issues. In: The choice modelling approach to environmental valuation. Edward Elgar Publishing; 2001. p. 13\u201336."},{"key":"1655_CR38","unstructured":"Huntington\u2019s Disease Society of America. Genetic testing protocol for Huntington\u2019s disease 2016 [Available from: https:\/\/hdsa.org\/wp-content\/uploads\/2015\/02\/HDSA-Gen-Testing-Protocol-for-HD.pdf."}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40273-026-01655-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-026-01655-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T16:20:30Z","timestamp":1788711630000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40273-026-01655-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,6]]},"references-count":38,"alternative-id":["1655"],"URL":"https:\/\/doi.org\/10.1007\/s40273-026-01655-8","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,6]]},"assertion":[{"value":"19 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"P.G.S. and D.A.O. were employees of CEVR at the time of this project (and remain employees of CEVR)\u00a0and were supported in part by this grant. S.M.K., D.L.B., and M.V.L. were employees and stockholders in Ionis Pharmaceuticals at the time of this project (S.M.K., and M.V.L. remain employees of Ionis).","order":1,"name":"Ethics","label":"Conflicts of Interest\/Competing Interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Conduct of this study was approved and monitored by the institutional review boards at Tufts University (STUDY00004150; approval 10 October 2023) and NORC at the University of Chicago (IRB00000967; approval 31 August 2023).","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all participants to join the AmeriSpeak Panel","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors made significant contributions to the study design, interpretation of results, and\/or authorship of the manuscript. All authors certify that this work properly represents the findings of the study.","order":4,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data are available upon request.","order":5,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}}]}}